Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis

Zhang, Fei; Zhang, Yiyin; Jia, Zhenya; Wang, Hongyang; Gu, Kai

doi:10.7150/jca.28896

Cited by 24 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Starting in 1989, carboplatin confirmed clinical relevance as an antineoplastic agent (in combination with other chemotherapeutics) for advanced ovarian carcinoma [ 10 ], head and neck cancer [ 11 ], and lung cancer [ 12 ]. The latest worldwide accepted platinum-based chemotherapeutic (2002), oxaliplatin, is used as a part of the therapeutic protocols for metastatic colorectal cancer [ 13 ], advanced gastric [ 14 ] and ovarian cancer [ 15 ].…”

Section: Therapeutic Indications For Platinum-based Chemotherapymentioning

confidence: 99%

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review

Stanković

Selaković

Mihailović

et al. 2020

IJMS

View full text Add to dashboard Cite

Cancer represents one of the most pernicious public health problems with a high mortality rate among patients worldwide. Chemotherapy is one of the major therapeutic approaches for the treatment of various malignancies. Platinum-based drugs (cisplatin, oxaliplatin, carboplatin, etc.) are highly effective chemotherapeutic drugs used for the treatment of several types of malignancies, but their application and dosage are limited by their toxic effects on various systems, including neurotoxicity. Simultaneously, researchers have tried to improve the survival rate and quality of life of cancer patients and decrease the toxicity of platinum-containing drugs by combining them with non-chemotherapy-based drugs, dietary supplements and/or antioxidants. Additionally, recent studies have shown that the root cause for the many side effects of platinum chemotherapeutics involves the production of reactive oxygen species (ROS) in naive cells. Therefore, suppression of ROS generation and their inactivation with antioxidants represents an appropriate approach for platinum drug-induced toxicities. The aim of this paper is to present an updated review of the protective effects of different antioxidant agents (vitamins, dietary antioxidants and supplements, medicaments, medicinal plants and their bioactive compounds) against the neurotoxicity induced by platinum-based chemotherapeutics. This review highlights the high potential of plant antioxidants as adjuvant strategies in chemotherapy with platinum drugs.

show abstract

Section: Therapeutic Indications For Platinum-based Chemotherapymentioning

confidence: 99%

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review

Stanković

Selaković

Mihailović

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Oxaliplatin (OXAL; Eloxatin ® , trans-1-diaminocyclohexane oxaliplatinum, C 8 H 14 N 2 O 4 Pt, (PubChem CID: 43805)) was acquired from Sanofi-Aventis (New York, NY, USA); ivabradine, protopine (4,6,7,14-tetrahydro-5-methylbis [1,3] The medium or solution was commonly filtered using a 0.22 µm pore filter.…”

Section: Chemicals Drugs and Solutionsmentioning

confidence: 99%

“…Oxaliplatin (OXAL, Eloxatin ® ) belongs to a family of platinum-based chemotherapeutic compounds. In combination with 5-fluorouracil, this drug has been ever-increasingly used in the treatment of advanced colorectal or gastric cancer [1][2][3]. Despite the good safety profile, its use has been well-established to confer susceptibility to peripheral neuropathy, affecting sensory and motor nerve fibers, explaining its unsuitability for long-term treatment [1,[4][5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Characterization in Dual Activation by Oxaliplatin, a Platinum-Based Chemotherapeutic Agent of Hyperpolarization-Activated Cation and Electroporation-Induced Currents

Chang

Gao

et al. 2020

IJMS

View full text Add to dashboard Cite

Oxaliplatin (OXAL) is regarded as a platinum-based anti-neoplastic agent. However, its perturbations on membrane ionic currents in neurons and neuroendocrine or endocrine cells are largely unclear, though peripheral neuropathy has been noted during its long-term administration. In this study, we investigated how the presence of OXAL and other related compounds can interact with two types of inward currents; namely, hyperpolarization-activated cation current (Ih) and membrane electroporation-induced current (IMEP). OXAL increased the amplitude or activation rate constant of Ih in a concentration-dependent manner with effective EC50 or KD values of 3.2 or 6.4 μM, respectively, in pituitary GH3 cells. The stimulation by this agent of Ih could be attenuated by subsequent addition of ivabradine, protopine, or dexmedetomidine. Cell exposure to OXAL (3 μM) resulted in an approximately 11 mV rightward shift in Ih activation along the voltage axis with minimal changes in the gating charge of the curve. The exposure to OXAL also effected an elevation in area of the voltage-dependent hysteresis elicited by long-lasting triangular ramp. Additionally, its application resulted in an increase in the amplitude of IMEP elicited by large hyperpolarization in GH3 cells with an EC50 value of 1.3 μM. However, in the continued presence of OXAL, further addition of ivabradine, protopine, or dexmedetomidine always resulted in failure to attenuate the OXAL-induced increase of IMEP amplitude effectively. Averaged current-voltage relation of membrane electroporation-induced current (IMEP) was altered in the presence of OXAL. In pituitary R1220 cells, OXAL-stimulated Ih remained effective. In Rolf B1.T olfactory sensory neurons, this agent was also observed to increase IMEP in a concentration-dependent manner. In light of the findings from this study, OXAL-mediated increases of Ih and IMEP may coincide and then synergistically act to increase the amplitude of inward currents, raising the membrane excitability of electrically excitable cells, if similar in vivo findings occur.

show abstract

“…Evidence was also obtained in support of the modified DCF (mDCF) regimens with the substitution of oral 5-FU prodrugs for continuous infusion of 5-FU or the substitution of oxaliplatin for cisplatin. [36][37][38] Moreover, DCF/mDCF was investigated as a NAC for GC in an attempt to enhance the resection rate, which finally resulted in improved survival. [39][40][41] More importantly, encouraging results were witnessed in some unresectable highly advanced GC patients who obtained conversion gastrectomy following the NAC with DCF/DCS.…”

Section: Discussionmentioning

confidence: 99%

<p>Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis</p>

Zhang¹,

Huang²,

Wei³

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: What is the optimal neoadjuvant chemotherapy (NAC) regimen for locally advanced gastric cancer (LAGC) remains debatable. The objective of this study was to compare the efficacy of docetaxel+oxaliplatin+S-1 (DOS) vs oxaliplatin+S-1 (SOX) as NAC for LAGC. Methods: Data of 248 LAGC patients who received either DOS or SOX as NAC in our hospital between January 2010 and January 2018 were reviewed retrospectively. Propensity score matched (PSM) analysis was applied to minimize the selection bias in both groups. Prognostic factors were screened by univariate and multivariate Cox regression analyses. Results: Of the 248 LAGC patients included, 180 patients were subjected to the PSM analysis. Patients in DOS group showed a better tumor response to NAC, higher radical resection rate and R0 resection rate than those in SOX group. The overall survival (OS) rate in DOS group was better than that in SOX group, although the overall incidence of Grade 3/4 NAC-related toxicity in DOS group was higher, as represented by leukopenia and neutropenia. Multivariate analysis revealed that the NAC regimen, cTNM stage and the R0 resection rate were independent prognostic factors. In addition, patients with TLND less than 16 population showed a worse OS rate. Subgroup analysis indicated that patients benefited from the addition of docetaxel regardless of the clinical T stage, but those with high clinical N stages (N2-3) did not. Conclusion: DOS is a safe and feasible NAC regimen for LAGC, which is worth popularizing in clinical practice.

show abstract

Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis

Cited by 24 publications

References 20 publications

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review

Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics—A Review

Characterization in Dual Activation by Oxaliplatin, a Platinum-Based Chemotherapeutic Agent of Hyperpolarization-Activated Cation and Electroporation-Induced Currents

<p>Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis</p>

Contact Info

Product

Resources

About